Affimed (NASDAQ:AFMD) Sees Large Decline in Short Interest

Affimed (NASDAQ:AFMD) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 653,600 shares, a drop of 5.8% from the September 15th total of 694,100 shares. Based on an average trading volume of 92,100 shares, the days-to-cover ratio is presently 7.1 days. Currently, 5.0% of the shares of the stock are sold short.

Institutional Investors Weigh In On Affimed

A hedge fund recently bought a new stake in Affimed stock. Choreo LLC acquired a new stake in shares of Affimed (NASDAQ:AFMD) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned about 0.07% of Affimed at the end of the most recent quarter. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Price Performance

AFMD stock opened at $3.13 on Wednesday. The company’s 50 day moving average is $3.79 and its 200 day moving average is $4.88. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. Affimed has a 1-year low of $2.23 and a 1-year high of $8.95.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. Analysts expect that Affimed will post -4.25 EPS for the current fiscal year.

Analyst Ratings Changes

AFMD has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Affimed currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.